vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Affinity Bancshares, Inc. (AFBI). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $8.6M, roughly 1.3× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs 23.5%, a 1.4% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 12.8%). Over the past eight quarters, Affinity Bancshares, Inc.'s revenue compounded faster (8.1% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs AFBI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $8.6M |
| Net Profit | $2.5M | $2.1M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 35.9% |
| Net Margin | 23.5% | 24.9% |
| Revenue YoY | 522.2% | 12.8% |
| Net Profit YoY | 112.7% | 58.5% |
| EPS (diluted) | $0.01 | $0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $8.4M | ||
| Q2 25 | $10.7M | $8.3M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | — | $8.0M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | — | $7.3M |
| Q4 25 | — | $2.1M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $2.5M | $2.2M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | $1.3M |
| Q4 25 | — | 35.9% | ||
| Q3 25 | — | 34.9% | ||
| Q2 25 | 13.9% | 34.1% | ||
| Q1 25 | — | 30.8% | ||
| Q4 24 | — | 21.1% | ||
| Q3 24 | — | 28.5% | ||
| Q2 24 | — | 16.2% | ||
| Q1 24 | — | 24.0% |
| Q4 25 | — | 24.9% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | 23.5% | 25.9% | ||
| Q1 25 | — | 23.4% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | — | 21.7% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 18.2% |
| Q4 25 | — | $0.34 | ||
| Q3 25 | — | $0.34 | ||
| Q2 25 | $0.01 | $0.33 | ||
| Q1 25 | — | $0.28 | ||
| Q4 24 | — | $0.21 | ||
| Q3 24 | — | $0.26 | ||
| Q2 24 | — | $0.16 | ||
| Q1 24 | — | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $53.9M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $127.0M |
| Total Assets | $103.3M | $881.7M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $53.9M | ||
| Q3 25 | — | $84.8M | ||
| Q2 25 | $37.4M | $89.7M | ||
| Q1 25 | — | $74.7M | ||
| Q4 24 | — | $41.4M | ||
| Q3 24 | — | $52.3M | ||
| Q2 24 | — | $50.4M | ||
| Q1 24 | — | $61.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $127.0M | ||
| Q3 25 | — | $125.4M | ||
| Q2 25 | $83.0M | $124.1M | ||
| Q1 25 | — | $122.3M | ||
| Q4 24 | — | $129.1M | ||
| Q3 24 | — | $128.4M | ||
| Q2 24 | — | $125.1M | ||
| Q1 24 | — | $123.3M |
| Q4 25 | — | $881.7M | ||
| Q3 25 | — | $925.2M | ||
| Q2 25 | $103.3M | $933.8M | ||
| Q1 25 | — | $912.5M | ||
| Q4 24 | — | $866.8M | ||
| Q3 24 | — | $878.6M | ||
| Q2 24 | — | $873.6M | ||
| Q1 24 | — | $869.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $11.6M |
| Free Cash FlowOCF − Capex | — | $11.2M |
| FCF MarginFCF / Revenue | — | 130.9% |
| Capex IntensityCapex / Revenue | 0.0% | 4.9% |
| Cash ConversionOCF / Net Profit | -6.24× | 5.46× |
| TTM Free Cash FlowTrailing 4 quarters | — | $20.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | $-15.7M | $3.8M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $619.0K | ||
| Q1 24 | — | $1.2M |
| Q4 25 | — | $11.2M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.7M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | $6.4M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $489.0K | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | 130.9% | ||
| Q3 25 | — | 43.3% | ||
| Q2 25 | — | 44.0% | ||
| Q1 25 | — | 22.7% | ||
| Q4 24 | — | 83.9% | ||
| Q3 24 | — | 49.5% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 14.8% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 5.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 1.8% |
| Q4 25 | — | 5.46× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | -6.24× | 1.75× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | 5.05× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
